Dual action of epigallocatechin-3-gallate in virus-induced cell Injury.

Publication date: Nov 28, 2023

Viral infections cause damage and long-term injury to infected human tissues, demanding therapy with antiviral and wound healing medications. Consequently, safe phytochemical molecules that may control viral infections with an ability to provide wound healing to viral-induced tissue injuries, either topically or systemically, are advantageous. Herein, we hypothesized that epigallocatechin-3-gallate (EGCG), the most abundant polyphenol in green tea, might be effective as a wound healing, antiviral, and antifibrotic therapy. The antiviral activities of EGCG against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Herpes simplex virus type 2 (HSV-2) as well as its wound healing activities against different monolayer tissue (continuous and primary) systems were investigated. Consider its possible wound-healing advantages as well. To determine the safe concentrations of EGCG in green monkey kidney (Vero) and Vero-E6 cell lines, MTT assay was performed and showed high CC values of 405. 1 and 322. 9 μM, respectively. The antiviral activities of EGCG against SARS-CoV-2 and HSV-2, measured as half-maximal concentration 50 (IC) concentrations, were 36. 28 and 59. 88 μM, respectively. These results confirm that the EGCG has remarkable viral inhibitory activities and could successfully suppress the replication of SARS-CoV-2 and HSV-2 in vitro with acceptable selectivity indices (SI) of 11. 16 and 5. 39, respectively. In parallel, the EGCG exhibits significant and dose/time-dependent anti-migration effects in human breast cancer cells (MCF-7), its resistant variation (MCF-7), and human skin fibroblast (HSF) indicating their potential to heal injuries in different internal and topical mammalian systems. The EGCG has proven to be an efficient antiviral against SARS-CoV-2 and HSV-2, as well as a wound-healing phytochemical. We assume that EGCG may be a promising option for slowing the course of acute cellular damage induced by systemic (Coronavirus Disease 2019 (COVID-19)) or topical (HSV-2) viral infections.

Concepts Keywords
Biotechnol Antiviral activity
Coronavirus Cellular injury
Efficient COVID-19
Therapy Green tea extract
Herpes simplex virus
Wound healing


Type Source Name
drug DRUGBANK Epigallocatechin
disease IDO cell
disease MESH Viral infections
drug DRUGBANK Epigallocatechin gallate
drug DRUGBANK Green tea leaf
disease VO effective
disease VO Severe acute respiratory syndrome coronavirus 2
disease IDO assay
disease IDO replication
disease VO dose
disease VO time
disease MESH breast cancer
pathway KEGG Breast cancer
disease VO efficient
disease MESH Coronavirus Disease 2019
disease MESH Herpes simplex

Original Article

(Visited 1 times, 1 visits today)